Primary mediastinal large B-cell lymphoma (PMLBCL) in Chinese patients: clinical characteristics and prognostic factors

被引：22

作者：

Zhu, Ying-Jie ^{[1
]}

Huang, Jia-Jia ^{[1
]}

Xia, Yi ^{[1
]}

Zhao, Wei ^{[1
]}

Jiang, Wen-Qi ^{[1
]}

Lin, Tong-Yu ^{[1
]}

Huang, Hui-Qiang ^{[1
]}

Li, Zhi-Ming ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Dept Med Oncol, State Key Lab Oncol So China, Canc Ctr, Guangzhou 510275, Guangdong, Peoples R China

来源：

INTERNATIONAL JOURNAL OF HEMATOLOGY | 2011年 / 94卷 / 02期

关键词：

Primary mediastinal large B-cell lymphoma; Prognostic factor; Radiotherapy; Serum albumin; CHOP-LIKE CHEMOTHERAPY; HODGKINS-DISEASE; RESPONSE CRITERIA; BRITISH-COLUMBIA; PLUS RITUXIMAB; SERUM-ALBUMIN; THERAPY; CLASSIFICATION; EXPERIENCE; NEOPLASMS;

D O I：

10.1007/s12185-011-0898-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Primary mediastinal large B-cell lymphoma (PMLBCL) is a unique clinico-pathological subtype, for which there is no optimal therapy yet. We evaluated clinical characteristics and prognostic factors in 39 consecutive, previously untreated Chinese patients with PMLBCL. The median age was 28 years (range 16-72 years). The majority of patients were stage I/II (23 cases, 59%). Bulky mediastinal mass was present in 18 cases (46%). The 3-year overall survival (OS) and progression-free survival (PFS) rates were 70 and 64%, respectively. Cox regression analysis showed that low serum albumin was an independent prognostic predictor of both OS (P = 0.002) and PFS (P = 0.001). Other prognostic factors for OS were extra-thoracic involvement (P = 0.016) and B symptoms (with borderline significance, P = 0.053). The addition of radiotherapy to chemotherapy seemed to have a favourable impact on OS (P = 0.034) and PFS (P = 0.039). The addition of rituximab to chemotherapy improved the survival trend, but added no significant benefit (OS: 57 vs. 84%, P = 0.287; PFS: 53 vs. 73%, P = 0.371). Our data additionally suggest that low serum albumin is a novel prognostic predictor for PMLBCL, and could be useful in determining treatment options in the clinic.

引用

页码：178 / 184

页数：7

共 50 条

[1] Primary mediastinal large B-cell lymphoma (PMLBCL) in Chinese patients: clinical characteristics and prognostic factors
Ying-Jie Zhu
Jia-Jia Huang
Yi Xia
Wei Zhao
Wen-Qi Jiang
Tong-Yu Lin
Hui-Qiang Huang
Zhi-Ming Li
International Journal of Hematology, 2011, 94 : 178 - 184
[2] Lack of clinical risk factors in patients diagnosed with primary mediastinal large-B-cell lymphoma (PMLBCL).
Smith, RP
Nasta, SD
Glatstein, E
Schuster, SJ
BLOOD, 2003, 102 (11) : 281B - 281B
[3] Prognostic factors and survival of patients with primary mediastinal large B-cell lymphoma.
Nowakowski, GS
Kaur, P
Macon, WR
Habermann, TM
Ristow, K
Ansell, SM
Witzig, TE
Markovic, SN
Porrata, LF
Micallef, IN
Johnston, PB
Colgan, JP
Inwards, DJ
BLOOD, 2005, 106 (11) : 254B - 255B
[4] Addition of rituximab to CHOP greatly improves the outcome of patients with primary mediastinal large B-cell lymphoma (PMLBCL)
Vassilakopoulos, T. P.
Pangalis, G.
Galani, Z.
Sachanas, S.
Katsigiannis, A.
Vrakidou, E.
Poziopoulos, C.
Constantinou, N.
Repoussis, P.
Dimopoulou, M.
Kokoris, S.
Michali, E.
Dimitriadou, E.
Masouridis, S.
Siakantaris, M.
Kalpadakis, C.
Kyrtsonis, M.
Panayiotidis, P.
Poussou, P.
Angelopoulou, M.
ANNALS OF ONCOLOGY, 2008, 19 : 188 - 188
[5] PROGNOSTIC FACTORS, MANAGEMENT AND OUTCOME OF AN INTERNATIONAL SERIES OF 41 PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) AND CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT
Tarantino, V.
Cabras, G.
Ferrara, F.
Zinzani, P.
Arcaini, L.
Castellino, A.
Tucci, A.
Cocito, F.
Davies, A.
Chalup, M. Salvador
Cwynarski, K.
Nogueira, F. L.
Petrucci, L.
Muzi, C.
Onofrillo, D.
Ferrario, A.
Ramakrishnan, P.
Scalzulli, P. R.
Tani, M.
Tisi, M. C.
Papageorgiou, S.
Calimeri, T.
Sassone, M. C.
Angelillo, P.
Foppoli, M.
Dimou, M.
Ponzoni, M.
Iannitto, E.
Vassilakropoulos, T. P.
Ferreri, A. J. M.
HAEMATOLOGICA, 2021, 106 (10) : 23 - 24
[6] Clinical characteristics and prognostic analysis of Chinese patients with diffuse large B-cell lymphoma
Ke, Xiaoyan
Wang, Jing
Gao, Zifen
Zhao, Lingzhi
Li, Min
Jing, Hongmei
Wang, Jijun
Zhao, Wei
Gilbert, Heather
Yang, Xiao-Feng
BLOOD CELLS MOLECULES AND DISEASES, 2010, 44 (01) : 55 - 61
[7] Clinical and immunomorphological characteristics of primary mediastinal large B-cell lymphoma.
Mazurok, L. A.
Kolomeitsev, O. A.
Probatova, N. A.
Pavlovskaya, A. I.
Kondratyeva, T. T.
Kosukhina, N. V.
Sholokhova, E. N.
Trofimova, O. P.
Sorokin, E. N.
Tumyan, G. S.
Poddubnaya, I. V.
Tupitsyn, N. N.
Osmanov, D. Sh.
GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2006, 51 (04): : 15 - 21
[8] The Role of PET-SCAN in the Evaluation of Response Assessment in Patients with Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
Rondogianni, P.
Vassilakopoulos, T.
Drougkas, D.
Vlontzou, E.
Exarchos, D.
Skylakaki, M.
Datseris, I.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S373 - S374
[9] Immunohistochemical Prognostic Markers in Primary Mediastinal Large B-Cell Lymphoma
Bledsoe, J. R.
Hasserjian, R. P.
Soumerai, J. D.
Boyer, D. F.
Nishino, H. T.
Ferry, J. A.
Harris, N. L.
Abramson, J. S.
Sohani, A. R.
LABORATORY INVESTIGATION, 2014, 94 : 336A - 336A
[10] PROGNOSTIC FACTORS FOR THE OUTCOME OF PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) UNDER CHEMOTHERAPY WITH RITUXIMAB-CHOP (R-CHOP) WITH OR WITHOUT RADIOTHERAP
Vassilakopoulos, T.
Angelopoulou, M.
Pangalis, G.
Katsigiannis, A.
Papageorgiou, S.
Vrakidou, E.
Poziopoulos, C.
Constantinou, N.
Repoussis, P.
Dimopoulou, M.
Kokoris, S.
Dimou, M.
Kyrtsonis, M.
Panayiotidis, P.
Dervenoulas, J.
Roussou, P.
Beris, P.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 116 - 116

← 1 2 3 4 5 →